Erudio Healtherudio.com
Drug
Elacestrant trials: what clinicians said in public
No HCP commentary report on a trial studying elacestrant yet. Erudio has found public clinician commentary on 6 clinical trials studying elacestrant, including ADELA, CAPELA, ELECTRA and TREAT ctDNA. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| TREAT ctDNA NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | ER+/HER2- breast cancer with ctDNA relapse | Phase 3 | Deep | View | |||
| ELECTRA NCT05386108 · Stemline Therapeutics, Inc. DeepView → | ER+/HER2- breast cancer with brain metastasis | Phase 1/Phase 2 | Deep | View | |||
| ADELA NCT06382948 · MedSIR StandardView → | ESR1-mutated ER+/HER2- advanced breast cancer after CDK4/6 inhibitors | Phase 3 | Standard | View | |||
| CAPELA NCT07222215 · Kristina A. Fanucci FocusedView → | advanced estrogen receptor-positive HER2-negative breast cancer | Phase 2 | Focused | View | |||
| ERADICATE NCT07198724 · Kristina A. Fanucci FocusedView → | endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||
| ADAPTela NCT07242352 · Women's Cancer Study Group GmbH FocusedView → | Not given | Phase 3 | Focused | View | |||